Amgen (NASDAQ:AMGN) Price Target Raised to $400.00

Amgen (NASDAQ:AMGN) had its price objective upped by Cantor Fitzgerald from $350.00 to $400.00 in a report published on Tuesday morning, MarketBeat.com reports. The brokerage currently has a neutral rating on the medical research company’s stock.

Several other equities research analysts have also commented on AMGN. Wells Fargo & Company boosted their price target on Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Citigroup lifted their price objective on Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Truist Financial boosted their target price on Amgen from $340.00 to $362.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. The Goldman Sachs Group set a $389.00 target price on Amgen in a report on Friday, June 5th. Finally, Barclays raised their price target on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $380.43.

Amgen Stock Down 2.0%

Shares of NASDAQ AMGN opened at $433.73 on Tuesday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen has a 52 week low of $269.77 and a 52 week high of $443.20. The firm has a 50-day moving average price of $377.35 and a 200 day moving average price of $361.40. The stock has a market capitalization of $234.49 billion, a price-to-earnings ratio of 26.96, a price-to-earnings-growth ratio of 4.09 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period in the prior year, the business posted $6.02 earnings per share. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts anticipate that Amgen will post 22.89 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is 62.65%.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock worth $2,540,926 over the last 90 days. Company insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On Amgen

Hedge funds and other institutional investors have recently modified their holdings of the company. Adell Harriman & Carpenter Inc. grew its stake in Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after purchasing an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Amgen in the fourth quarter valued at about $22,441,000. Sigma Planning Corp raised its stake in Amgen by 24.0% during the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock valued at $5,889,000 after buying an additional 3,488 shares in the last quarter. National Pension Service raised its stake in Amgen by 4.7% during the fourth quarter. National Pension Service now owns 1,239,549 shares of the medical research company’s stock valued at $405,717,000 after buying an additional 55,489 shares in the last quarter. Finally, Integrated Advisors Network LLC lifted its holdings in Amgen by 50.5% during the 1st quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock worth $6,664,000 after buying an additional 6,356 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Unusually heavy call-option activity points to increased bullish positioning. Investors purchased 79,035 call options, roughly 931% above typical volume, although options activity is speculative and does not guarantee future gains.
• Positive Sentiment: Argus raised its price target from $375 to $460 and upgraded Amgen to “Buy,” adding to the series of favorable analyst views. Argus price target report
• Positive Sentiment: Mizuho and Cantor Fitzgerald analysts also projected further appreciation for Amgen, reinforcing the bullish sentiment around the company’s earnings performance and pipeline. Mizuho Amgen forecast Cantor Fitzgerald Amgen outlook
• Positive Sentiment: Amgen has outperformed several major drugmakers in 2026, attracting investor interest as markets favor profitable pharmaceutical companies even without an obesity-drug franchise. Drugmaker stock performance comparison
• Neutral Sentiment: Biotech ETFs are benefiting from innovation, obesity-drug demand and merger activity, creating a favorable sector backdrop, though the article does not identify a specific new catalyst for Amgen. Biotech ETF growth article
• Negative Sentiment: Industry caution around obesity-drug development is a risk: investors are penalizing undifferentiated programs, and Amgen has reportedly trimmed some early-stage efforts. Obesity drug investment outlook

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.